Amino.Desk

Cagrilintide (and CagriSema)

Updated Nov 17, 2026 · Clinical review: pending

Cagrilintide is an experimental weekly injection from Novo Nordisk that mimics amylin, a hormone released with insulin that helps signal fullness. Combined with semaglutide it is called CagriSema, which is under FDA review. Neither is approved.

What it is

Cagrilintide is a long-acting version of amylin. It works on different receptors from GLP-1 drugs, so the idea behind CagriSema is to add two appetite signals together. The first drugs of each kind, pramlintide and exenatide, were both approved in 2005.

What the evidence shows

The grade is B rather than A because the strong evidence is for the combination. Vials sold online are cagrilintide alone, which has much less data, and nothing is known about their content.

Dosing used in the trials

There is no approved dose. In REDEFINE 1 the target was 2.4 mg of cagrilintide plus 2.4 mg of semaglutide once a week, reached by gradual increases; about 75% of participants reached the full dose. Investigators could keep people on a lower dose if needed.

Legal status

Novo Nordisk filed for FDA approval of CagriSema in December 2025 and has said it expects a decision in the fourth quarter of 2026. The FDA states that cagrilintide cannot be used in compounding under federal law, so "compounded CagriSema" and research vials are unapproved and unverified.

Common questions

Is cagrilintide FDA-approved?

No. Novo Nordisk filed for approval of CagriSema, the combination with semaglutide, in December 2025 and has said it expects a decision in the fourth quarter of 2026.

How much weight did people lose on CagriSema?

In REDEFINE 1, average weight loss over 68 weeks was 20.4% counting everyone assigned to it, and 22.7% among people who stayed on treatment. That evidence is for the combination, not cagrilintide alone.

Can cagrilintide be compounded?

No. The FDA states that cagrilintide cannot be used in compounding under federal law.

Added in the latest update. These answers summarize the sections above; sources are listed below.

Ask an AI about this page

Opens the assistant with a question about this page already typed in. You can edit it before sending.

Ask ChatGPTAsk ClaudeAsk Perplexity

These are outside services. Amino Desk does not control or review their answers, and an AI summary is not medical advice. Check anything important against the sources below.

Sources

Free field guide

Forty peptides and GLP-1s: who can legally get what, how strong the evidence is, and what to check before you pay. Plus one short email a week on what changed.

Leave at any time. We do not sell or share your address. Privacy